Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly & Co.

www.lilly.com

Latest From Eli Lilly & Co.

Preparing For The NASH Market: A Conversation With Genfit CEO Pascal Prigent And COO Dean Hum

As Genfit nears Phase III data for its NASH candidate elafibranor, it has promoted a new CEO and is working ahead on both an NDA filing and facing the commercial challenges of a new therapeutic space.

C-Suite Speaks Commercial

Lilly Calls Time On UK Neuroscience Research Center

The closure reflects the consolidation of neuroscience research in Cambridge, Mass, and Brexit is not to blame, says Lilly.

United Kingdom Companies

Shake It Off? Japan Mulls Routes Out Of Bioventure Doldrums

The long-recurring theme of how effectively to foster Japan’s bioventure sector again emerged as a key thread at recent major industry meeting, while the broader topic of effective partnering occupied the minds of industry and academia alike.

Japan Gene Therapy

J&J's Tremfya Gets Its Blockbuster Wings

The psoriasis drug was one of 10 J&J medicines that grew double digits in the third quarter, leading the company to raise guidance for the year.

Sales & Earnings Immune Disorders
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register